291 related articles for article (PubMed ID: 26236409)
1. How to treat actinic keratosis? An update.
Costa C; Scalvenzi M; Ayala F; Fabbrocini G; Monfrecola G
J Dermatol Case Rep; 2015 Jun; 9(2):29-35. PubMed ID: 26236409
[TBL] [Abstract][Full Text] [Related]
2. Actinic keratosis: rationale and management.
Dodds A; Chia A; Shumack S
Dermatol Ther (Heidelb); 2014 Jun; 4(1):11-31. PubMed ID: 24627245
[TBL] [Abstract][Full Text] [Related]
3. Field Cancerization Therapies for Management of Actinic Keratosis: A Narrative Review.
Jetter N; Chandan N; Wang S; Tsoukas M
Am J Clin Dermatol; 2018 Aug; 19(4):543-557. PubMed ID: 29582369
[TBL] [Abstract][Full Text] [Related]
4. Actinic keratosis - review for clinical practice.
de Oliveira ECV; da Motta VRV; Pantoja PC; Ilha CSO; Magalhães RF; Galadari H; Leonardi GR
Int J Dermatol; 2019 Apr; 58(4):400-407. PubMed ID: 30070357
[TBL] [Abstract][Full Text] [Related]
5. Non-invasive monitoring of subclinical and clinical actinic keratosis of face and scalp under topical treatment with ingenol mebutate gel 150 mcg/g by means of reflectance confocal microscopy and optical coherence tomography: New perspectives and comparison of diagnostic techniques.
Ruini C; Hartmann D; Bastian M; Ruzicka T; French LE; Berking C; von Braunmühl T
J Biophotonics; 2019 Jul; 12(7):e201800391. PubMed ID: 30653833
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy of actinic keratosis: an update.
Berman B; Amini S
Expert Opin Pharmacother; 2012 Sep; 13(13):1847-71. PubMed ID: 22888917
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis.
Stockfleth E; Bastian M
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):911-918. PubMed ID: 30074409
[TBL] [Abstract][Full Text] [Related]
8. The paradigm shift in treating actinic keratosis: a comprehensive strategy.
Stockfleth E
J Drugs Dermatol; 2012 Dec; 11(12):1462-7. PubMed ID: 23377517
[TBL] [Abstract][Full Text] [Related]
9. Attitudes among dermatologists regarding actinic keratosis treatment options.
Moretta G; Samela T; Sampogna F; Ricci F; Carlesimo F; Panebianco A; D'Erme AM; Di Lella G; Pallotta S; Dellambra E; Abeni D; Fania L
Dermatol Reports; 2022 Sep; 14(3):9392. PubMed ID: 36267162
[TBL] [Abstract][Full Text] [Related]
10. The importance of treating the field in actinic keratosis.
Stockfleth E
J Eur Acad Dermatol Venereol; 2017 Mar; 31 Suppl 2():8-11. PubMed ID: 28263021
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy of actinic keratosis.
Berman B; Amini S; Valins W; Block S
Expert Opin Pharmacother; 2009 Dec; 10(18):3015-31. PubMed ID: 19925043
[TBL] [Abstract][Full Text] [Related]
12. Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy.
Neri L; Peris K; Longo C; Calvieri S; Frascione P; Parodi A; Eibenschuz L; Bottoni U; Pellacani G;
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):93-107. PubMed ID: 29920789
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomic evaluations in the treatment of actinic keratoses.
Tolley K; Argenziano G; Calzavara-Pinton PG; Larsson T; Ryttig L
Int J Immunopathol Pharmacol; 2017 Jun; 30(2):178-181. PubMed ID: 28580871
[TBL] [Abstract][Full Text] [Related]
14. Topical management of actinic keratosis and field cancerisation.
Stockfleth E
G Ital Dermatol Venereol; 2009 Aug; 144(4):459-62. PubMed ID: 19755950
[TBL] [Abstract][Full Text] [Related]
15. Non-melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses.
Poulin Y; Lynde CW; Barber K; Vender R; Claveau J; Bourcier M; Ashkenas J;
J Cutan Med Surg; 2015; 19(3):227-38. PubMed ID: 25926621
[TBL] [Abstract][Full Text] [Related]
16. Treatment considerations in actinic keratosis.
Goldenberg G
J Eur Acad Dermatol Venereol; 2017 Mar; 31 Suppl 2():12-16. PubMed ID: 28263018
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and tolerability of field treatment of actinic keratosis with ingenol mebutate 0.015 % gel: a single center case series.
Bobyr I; Campanati A; Consales V; Giuliodori K; Scalise A; Offidani A
Springerplus; 2016; 5():627. PubMed ID: 27330893
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Ingenol Mebutate in the Treatment of Actinic Keratoses: A Pre- and Posttreatment Dermoscopic Comparative Analysis.
Carbotti M; Coppola R; Zanframundo S; Devirgiliis V; Panasiti V
Biomed Res Int; 2018; 2018():4381019. PubMed ID: 30246021
[TBL] [Abstract][Full Text] [Related]
19. Field cancerization: from molecular basis to selective field-directed management of actinic keratosis.
Philipp-Dormston WG
Curr Probl Dermatol; 2015; 46():115-21. PubMed ID: 25561215
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice.
Skroza N; Bernardini N; Proietti I; Potenza C
Ther Clin Risk Manag; 2018; 14():1879-1885. PubMed ID: 30323610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
